Biotech IPO Class of 2000: A Look at Development Pipelines
This article was originally published in Start Up
Executive Summary
For those companies in biotech's IPO class of 2000, having Phase III products, as opposed to just Phase I and II compounds, definitely does bring a boost in valuation.